The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.
 
Gregory Russell Pond
No Relationships to Disclose
 
Guru Sonpavde
Consulting or Advisory Role - Agensys; Argos Therapeutics; Bayer; Genentech; Merck; Novartis; Pfizer; Sanofi
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Onyx (Inst)
 
Melissa Plets
No Relationships to Disclose
 
Catherine M. Tangen
No Relationships to Disclose
 
Maha Hussain
Consulting or Advisory Role - AstraZeneca; Essa; Johnson & Johnson; Synthon
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech (Inst); Medivation (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Astex Pharmaceuticals; Clovis Oncology; Exelixis; Halozyme; Immunogen; Janssen; Lilly; LPath; Medivation; Novartis; Pfizer; Sanofi; Teva; US Diagnostic Services
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Janssen Biotech (Inst); Millennium (Inst); Oncogenex (Inst); Polaris (Inst)
 
Amir Goldkorn
No Relationships to Disclose
 
Mark Garzotto
Consulting or Advisory Role - Astellas Pharma; Bayer
Research Funding - Dendreon (Inst); Genomic Health (Inst)
 
Philip C. Mack
Honoraria - Guardant Health
Consulting or Advisory Role - Apton Biosystems; AstraZeneca; MolecularMD
Research Funding - Boehringer Ingelheim
Travel, Accommodations, Expenses - Guardant Health
 
Celestia S. Higano
Employment - Cell Therapeutics (I)
Leadership - Cell Therapeutics (I)
Stock and Other Ownership Interests - Cell Therapeutics (I)
Consulting or Advisory Role - AbbVie; Bayer; BHR Pharma; Dendreon; Ferring; Genentech; Johnson & Johnson; Medivation; Orion; Pfizer; Sanofi
Research Funding - Algeta/Bayer (Inst); Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Dendreon (Inst); Emergent BioSolutions (Inst); Exelixis (Inst); Genentech (Inst); Medivation (Inst); Millennium (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AbbVie; Amgen; Astellas Pharma; Bayer; Dendreon; Ferring; Genentech; Johnson & Johnson; Medivation; Ockham; Orion; Pfizer; Sanofi; Teva
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Cerulean Pharma; Janssen Biotech; Labceutics; Pfizer
Speakers' Bureau - Bayer; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
Ian Murchie Thompson
Consulting or Advisory Role - Exosome diagnostics; Magforce
Patents, Royalties, Other Intellectual Property - I have been involved in the establishment of a new company - NanoTX Therapeutics to commercialize a novel therapy for glioblastoma for our cancer center. I am on the Board of Directors and it has intellectual property developed by our cancer center.; I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
Przemyslaw Twardowski
No Relationships to Disclose
 
Peter J. Van Veldhuizen
No Relationships to Disclose
 
Neeraj Agarwal
Research Funding - amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Michael Anthony Carducci
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Blue Earth Diagnostics; Clovis Oncology; Medivation; Merck
 
Paul Monk
No Relationships to Disclose
 
David I. Quinn
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Dendreon; Fresenius Kabi; Genentech/Roche; Janssen Oncology; Medivation; Novartis; Pfizer
Consulting or Advisory Role - Algeta/Bayer; Astellas Pharma; Bristol-Myers Squibb; Dendreon; Genentech/Roche; Janssen Oncology; Medivation; Novartis; Pfizer
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
Expert Testimony - Medivation; Teva